Publications
July 22, 2024
Frontiers in Neurology
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
July 9, 2024
Science Signaling
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis
February 9, 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Posters & Presentations
June 2024
American Diabetes Association Scientific Sessions
The Anti-Myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity
June 2024
American Society of Clinical Oncology
Phase1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1inhibitor, combined with pembrolizumab in anti-PD1 resistant patients with advanced solid tumors: Updated results of expansion phase